Company: ANIX
Filing Date: 2025-09-10
Form Type: 10-Q
Source: 0001493152-25-013000
Chunk: 4

Company: Anixa Biosciences Inc
Filing Date: 2025-09-10
Form: 10-Q
Item: Part I, Item 1
Chunk 4
---
 $16,595  
    $(1,184) 
    $15,411

FOR
THE THREE MONTHS ENDED JULY 31, 2024 (UNAUDITED)

    Common
    Stock  
    Additional  

    Total  
    Non-  

    Shares  
    Par
    Value  
    Paid-in
     Capital  
    Accumulated
     Deficit  
    Treasury
     Stock  
    Shareholders’
    Equity  
    controlling
    Interest  
    Total
    Equity 

    Balance,
    April 30, 2024 
     32,006,460  
    $320  
    $257,893  
    $(234,590) 
    $-  
    $23,623  
    $(1,042) 
    $22,581 
  
    Stock
    option compensation to employees and directors 
     -  
     -  
     1,094  
     -  
     -  
     1,094  
     -  
     1,094 
  
    Stock
    options issued to consultants 
     -  
     -  
     23  
     -  
     -  
     23  
     -  
     23 
  
    Offering
    expenses related to an at-the-market offering 
     -  
     -  
     (45) 
     -  
     -  
     (45) 
     -  
     (45)
  
    Common
    stock issued upon exercise of stock options 
     80,000  
     1  
     193  
     -  
     -  
     194  
     -  
     194 
  
    Common
    stock issued to consultants 
     60,000  
     -  
     159  
     -  
     -  
     159  
     -  
     159 
  
    Net
    loss 
     -  
     -  
     -  
     (3,277) 
     -  
     (3,277) 
     (38) 
     (3,315)
  
    Balance,
    July